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Summary
Background Increasing numbers of individuals with cystic ﬁ brosis are becoming infected with the multidrug-resistant 
non-tuberculous mycobacterium (NTM) Mycobacterium abscessus, which causes progressive lung damage and is 
extremely challenging to treat. How this organism is acquired is not currently known, but there is growing concern 
that person-to-person transmission could occur. We aimed to deﬁ ne the mechanisms of acquisition of M abscessus in 
individuals with cystic ﬁ brosis.
Method Whole genome sequencing and antimicrobial susceptibility testing were done on 168 consecutive isolates of 
M abscessus from 31 patients attending an adult cystic ﬁ brosis centre in the UK between 2007 and 2011. In parallel, we 
undertook detailed environmental testing for NTM and deﬁ ned potential opportunities for transmission between 
patients both in and out of hospital using epidemiological data and social network analysis.
Findings Phylogenetic analysis revealed two clustered outbreaks of near-identical isolates of the M abscessus subspecies 
massiliense (from 11 patients), diﬀ ering by less than ten base pairs. This variation represents less diversity than that 
seen within isolates from a single individual, strongly indicating between-patient transmission. All patients within 
these clusters had numerous opportunities for within-hospital transmission from other individuals, while 
comprehensive environmental sampling, initiated during the outbreak, failed to detect any potential point source of 
NTM infection. The clusters of M abscessus subspecies massiliense showed evidence of transmission of mutations 
acquired during infection of an individual to other patients. Thus, isolates with constitutive resistance to amikacin 
and clarithromycin were isolated from several individuals never previously exposed to long-term macrolides or 
aminoglycosides, further indicating cross-infection.
Interpretation  Whole genome sequencing has revealed frequent transmission of multidrug resistant NTM between 
patients with cystic ﬁ brosis despite conventional cross-infection measures. Although the exact transmission route is 
yet to be established, our epidemiological analysis suggests that it could be indirect.
Funding  The Wellcome Trust, Papworth Hospital, NIHR Cambridge Biomedical Research Centre, UK Health 
Protection Agency, Medical Research Council, and the UKCRC Translational Infection Research Initiative.
Introduction
Non-tuberculous mycobacteria (NTM) are ubiquitous 
environmental organisms that cause chronic pulmonary 
infection in patients with inﬂ ammatory lung diseases—
such as cystic ﬁ brosis, non-cystic ﬁ brosis bronchiectasis, 
and chronic obstructive pulmonary disease—as well as 
in certain individuals with no deﬁ nable risk factors.1,2 Of 
the rapidly growing NTM species, the multidrug resistant 
Mycobacterium abscessus has emerged as a major 
respiratory pathogen particularly in individuals with 
cystic ﬁ brosis, where it leads to accelerated decline in 
lung function3 and can prevent safe lung transplantation.4 
Treatment of M abscessus is challenging, requiring 
extended therapy with poorly tolerated combination 
antibiotics, and frequently fails.5,6
Recent evidence7,8 has suggested that M abscessus can be 
divided into three subspecies (subsp): Mycobacterium 
abscessus subsp abscessus, M abscessus subsp massiliense, 
and M abscessus subsp bolletii. These subspecies are not 
currently distinguished by hospital laboratories, but they 
could have diﬀ erent clinical behaviours.9,10 Worryingly, 
pulmonary infections with M abscessus have become 
more common. Studies from Taiwan,11 USA,12 and 
Australia13 have all reported signiﬁ cant increases in the 
prevalence of M abscessus pulmonary infection over the 
past decade. Between 3% and 10% of individuals with 
cystic ﬁ brosis in the USA and Europe are now infected 
with M abscessus,14,15 with increasing prevalence not 
attributable to changes in screening intensity or 
laboratory culture methods.16
The reasons for increased M abscessus infections in 
patients with cystic ﬁ brosis are unclear but could include: 
greater exposure to NTM from bioﬁ lms in showerheads,17 
the creation of permissive lung niches through increased 
inhaled antibiotic usage,18 and impairment of host anti-
mycobacterial immunity through autophagy inhibition by 
chronic azithromycin therapy.16 Although person-to-person 
transmission of NTM has never been deﬁ nitively proven, 
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the concern that M abscessus could be spread between 
patients with cystic ﬁ brosis has recently increased.
Previous studies have suggested independent acqui-
sition of NTM from the environment by patients with 
cystic ﬁ brosis. In the USA, Olivier and colleagues19 
analysed 140 NTM isolates (16% of which were 
M abscessus) obtained from cystic ﬁ brosis centres and 
found near-unique hsp65 sequences. In France, Sermet-
Gaudelus and colleagues20 examined M abscessus iso-
lates from 14 patients, and found them to be unique by 
pulsed ﬁ eld gel electrophoresis (PGFE). However, both 
studies had few patients with NTM from the same 
cystic ﬁ brosis centre and analysed patient cohorts from 
more than a decade ago. More recently a potential 
outbreak of M abscessus subsp massiliense was reported 
after the transfer of a smear-positive patient to a cystic 
ﬁ brosis centre in Seattle.21 Four other patients were 
identiﬁ ed as infected with a strain that was indis-
tinguishable by PFGE and PCR analysis from that of 
the index case. Other studies have also suggested that 
M abscessus isolates from patients attending the same 
hospital could be genetically very closely related.22,23 
However, deﬁ ni tive proof of person-to-person trans-
mission has been lack ing. Conventional typing methods 
such as PCR or PFGE do not have the molecular 
resolution to allow accurate analysis of the population 
structure and modes of acqui sition of mycobacteria, 
owing to their slow mutation rate. 
To understand how individuals with cystic ﬁ brosis 
acquire M abscessus infection and to establish whether 
patient-to-patient transmission does occur, we undertook 
whole genome sequencing on 168 consecutive isolates 
from 31 infected patients attending the Cambridge 
Centre for Lung Infection at Papworth Hospital, UK, a 
large adult cystic ﬁ brosis centre. 
Methods
Sample collection 
From October, 2007 to April, 2011, we collected and stored 
every isolate of NTM as frozen aliquots from myco-
bacterial growth indicator tube (MGIT) samples. We 
analysed all recoverable isolates from every patient with 
pulmonary M abscessus infection. After initial culture on 
solid media, we collected sweeps of M abscessus colonies 
to subculture (to remove contamination while main-
taining genetic diversity). One isolate was excluded 
because of likely culture contamination. We thereby 
obtained pure cultures of 168 separate isolates of 
M abscessus from 31 patients. DNA was extracted from all 
these isolates for sequencing and, in parallel, antibiotic 
susceptibility testing was done (appendix). The date and 
location of hospital attendances (inpatient and outpatient) 
and bronchoscopies were obtained for patients from the 
ﬁ rst date they were seen in Papworth until the end of the 
study period. Sampling was done on hospital water 
supplies, showerheads, and bronchoscopes, as well as 
local ponds and rivers. 
Whole genome sequencing and phylogenetic analysis
Multiplexed paired end sequencing was done on the 
Illumina Hiseq platform. Variation in the form of 
single nucleotide polymorphisms (SNPs) was detected 
using a mapping approach applying stringent ﬁ lters. A 
maxi mum likelihood tree was built using the SNPs 
detected. For more accurate phylogenetic analysis 
within individual subspecies, additional representative 
refer ences were assembled. To estimate mutation rate 
and the age of clusters, Bayesian inference was 
implemented in BEAST24 version 1.6.1, a program used 
for Bayesian Markov chain Monte Carlo analysis of 
genetic sequences (appendix). Raw reads were 
deposited on the European Nucleotide Archive under 
study acces sion number ERP001039
Statistical analysis 
Date and location data were analysed to identify possible 
cross-infection events between patients. Social network 
analysis was used to compare the occurrence of cross 
infection between genetically clustered and unclustered 
cases (appendix). Data were extracted from the following 
electronic systems: Patient Administration System 
(PAS), the Clinical Research Information System (CRIS), 
the Cardiovascular Information System (CVIS) and the 
Respiratory Physiology Database. Data for patient 
location was also collected from nursing handover notes 
and discrepancies were veriﬁ ed from the original notes. 
All clinical data were initially stored in Excel and 
subsequently managed using a SQL database. Analysis 
was done with Excel, Cytoscape, and Stata 12.0.
Role of the funding source
The sponsors of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding authors had full access to all 
the data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Clinical details, demographic information for infected 
patients, and dates of isolates analysed are given in the 
appendix. Using whole genome sequencing, we 
constructed a phylogenetic tree from M abscessus isolates 
obtained from patients within our adult cystic ﬁ brosis 
and bronchiectasis centre (ﬁ gure 1; appendix). We 
identiﬁ ed deep genetic divisions corresponding to the 
three M abscessus subspecies,26 which nevertheless 
showed high overall genetic similarity with an average 
nucleotide identity of 99·1%. Although combining 
M abscessus subsp massiliense and M abscessus subsp 
bolletii has been suggested,27 these are clearly as distinct 
from each other as each is from M abscessus subsp 
abscessus. Of the 31 patients, 13 were infected with 
M abscessus subsp abscessus, 15 with M abscessus subsp 
massiliense, and two with M abscessus subsp bolletii. One 
patient was coinfected with both M abscessus subsp 
See Online for appendix
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abscessus and M abscessus subsp massiliense and was 
excluded from further analysis. 
We noted tight clustering of isolates from each 
individual, indicating near-identical genomic sequences, 
and many examples of large genetic diﬀ erences between 
isolates from diﬀ erent individuals, consistent with 
independent acquisition by patients of genetically 
diverse organisms from the environment. However, 
among both M abscessus subsp abscessus and M abscessus 
subsp massiliense samples, there were also clear 
examples of grouping of isolates from diﬀ erent 
individuals (ﬁ gure 1). Within the M abscessus subsp 
abscessus cluster, isolates from six patients showed high 
levels of relatedness but were clearly segregated from 
one another. 
By contrast, within both M abscessus subsp massiliense 
clusters (ﬁ gure 1), we found that isolates from diﬀ erent 
individuals had near-identical genomic sequences that, 
on phylogenetic analysis, were often more closely related 
to each other than to other samples from the same 
individual. Furthermore, in cluster 2 the genetic diversity 
of isolates from patient 28 was entirely encompassed 
within that of samples from patient 2, indicating 
immediate relatedness by direct descent. These ﬁ ndings 
strongly indicate multiple episodes of transmission of 
M abscessus subsp massiliense between patients.
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Figure 1: Phylogenetic tree of M abscessus isolates indicates diﬀ erent modes of likely transmission
(A) Maximum likelihood tree of all isolates sequenced generated by mapping reads against the M abscessus subsp abscessus reference genome25 and building a midpoint rooted tree using the 
280 615 variable positions detected. The tree reveals the presence of the three subspecies of M abscessus (M abscessus subsp abscessus, M abscessus subsp massiliense, and M abscessus subsp bolletii) with 
evidence of tight clustering of isolates from each individual (denoted by a separate colour), and many examples of large genetic diﬀ erences between isolates from diﬀ erent individuals, consistent with 
independent acquisition of genetically diverse organisms from the environment. We identiﬁ ed tight clusters consisting of multiple patient isolates within the M abscessus subsp abscessus group 
(M abscessus subsp abscessus cluster); (B) and the M abscessus subsp massiliense group (M abscessus subsp massiliense cluster 1 and 2); (C) which was based on mapping against an assembled M abscessus 
subsp massiliense reference genome. The branches between the M abscessus subsp massiliense clusters are 95 and 90 SNPs in length but have been shortened for illustration purposes. Isolates from patients 
from Papworth Hospital (denoted by numbers) are also compared with other published whole genome sequences (grey) for M abscessus subsp abscessus (isolates from Malaysian patients without cystic 
ﬁ brosis [M93, M94, and M152]), M abscessus subsp massiliense (from Malaysian patients without cystic ﬁ brosis [M115, M154, M139]; from a French patient without cystic ﬁ brosis  [CCUG48898]; from a 
patient in Birmingham UK with cystic ﬁ brosis [47J26]; and from a surgical outbreak in Brazil [GO-06]) and M abscessus subsp bolletii (from a sputum isolate from France [CIP108541]). 
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The phylogeny was also supplemented with publicly 
available isolates from the UK, Brazil, and Malaysia. 
None of the additional isolates fell within the clusters 
identiﬁ ed, but were distributed broadly across the tree, 
indicating that our sample is representative of the species 
diversity. One isolate from a patient in Birmingham was 
found to be 76 base pairs diﬀ erent from one of the 
M abscessus subsp massiliense clusters, suggesting that 
this clade (M abscessus subsp massiliense cluster 1 and 2) 
is not speciﬁ c to Papworth. 
To further analyse the possibility of transmission of 
M abscessus subsp massiliense, we examined the 
distribution of genetic similarity between individual 
isolates, expressed as pairwise distances, and identiﬁ ed 
three distinct modes of similarity (ﬁ gure 2). The ﬁ rst 
mode, with greater than 10 000 base pair diﬀ erences, 
constitutes comparisons of isolates from diﬀ erent 
M abscessus subspecies and from non-clustered 
M abscessus strains. The second mode, encompassing 
pairwise diﬀ erences of 50–200 base pairs, is made up of 
comparisons of isolates from within the M abscessus 
subsp abscessus cluster and between diﬀ erent M abscessus 
subsp massiliense clusters. The ﬁ nal mode, with less than 
25 base pair diﬀ erences, represents the diversity of 
samples from single individuals and the similarity of 
diﬀ erent patients’ isolates within each M abscessus subsp 
massiliense cluster. 
These results suggest that for M abscessus subsp 
abscessus, patients have independently acquired either 
genetically diverse strains (non-clustered isolates) or a 
dominant circulating clone (loosely-clustered isolates). 
In the case of M abscessus subsp massiliense however, 
although some patients acquired strains which were 
unclustered, most have been infected with one of two 
clones. The genetic diﬀ erence between these patients’ 
isolates is often less than that among isolates from a 
single individual, strongly indicating transmission 
between patients.
We next examined the pattern of antibiotic resistance in 
M abscessus subsp abscessus and M abscessus subsp 
massiliense isolates obtained from patients before or shortly 
after starting treatment (table). We focused on macrolide 
and aminoglycoside resistance, since the underlying 
molecular mechanisms are well established and in vitro 
testing predicts clinical response to treatment.5,28 As 
expected, most M abscessus subsp abscessus isolates showed 
inducible macrolide resistance,29 known to be mediated 
through upregulation of the ribosomal methyltransferase 
erm(41), while all non-clustered M abscessus subsp 
massiliense isolates remained fully susceptible to 
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Figure 2: Histograms of SNP pairwise distances between isolates of the same subspecies
Distribution reveals clear distinctions between: pairwise diﬀ erences of more than 10 000 SNPs, comprising comparisons of isolates from diﬀ erent M abscessus 
subspecies and from non-clustered M abscessus strains; pairwise diﬀ erences of 50–200 SNPs, representing comparisons of isolates from within the M abscessus subsp 
abscessus cluster and between diﬀ erent M abscessus subsp massiliense clusters; and isolates with diﬀ erences of less than 25 SNPs, constituting the diversity of samples 
from single individuals (red) and that of diﬀ erent patients’ isolates within each M abscessus subsp massiliense cluster (blue). 
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clarithromycin after prolonged in vitro macrolide exposure, 
resulting from an inactivating erm(41) deletion found 
universally in this subspecies.29,30 However, M abscessus 
subsp massiliense isolates from cluster 1 and 2 were found 
to have high-level, constitutive macrolide resistance due to 
single point mutations in the 23S ribosomal rRNA 
(A2058C for cluster 1 and A2058G for cluster 2). Although 
constitutive macrolide resistance in NTM is thought to 
result from previous antibiotic exposure,31 we noted that 
three of the patients from cluster 1 had not previously 
taken long-term macrolide antibiotics, once again 
suggesting transmission between patients, rather than 
independent acquisition from the environment.
M abscessus subsp massiliense cluster 1 isolates showed 
high-level amikacin resistance (minimum inhibitory 
concentration [MIC] >64 mg/mL) owing to the same 
point mutation (A1408G) in their 16S ribosomal rRNA. 
Isolates from the presumed index case, patient 8, became 
resistant to aminoglycosides during NTM treatment with 
an amikacin-based regimen. Of the other patients in 
cluster 1, four had not previously taken nebulised 
aminoglycosides (table), again suggesting transmission 
of a resistant clone from patient 8.
Although not supported by our genetic data, we next 
examined whether an ongoing point source of infection 
might be responsible for the outbreak of each clustered 
M abscessus subsp massiliense clone. Given the period 
during which new patients were infected, any potential 
point source would have to be genetically stable and 
persistent in the environment for more than 3 years.
We ﬁ rst established whether patients infected with the 
transmitted M abscessus subsp massiliense clones might 
live close together or share the same potable water 
supply, which has been implicated as a possible source 
for acquisition of M abscessus.32 As shown in the appendix, 
patients infected with the clustered M abscessus subsp 
massiliense strains or the dominant M abscessus subsp 
abscessus clone are not geographically grouped and do not 
share the same home water supply. 
We also undertook extensive environmental sampling 
within the hospital cystic ﬁ brosis centre, which began 
during the outbreak in June, 2010. The hospital water 
Macrolide  response Aminoglycoside response
Prior chronic 
macrolide 
exposure
Clarithromycin 
sensitivity
Minimum inhibitory 
concentration 
(μg/mL), day 5/14
Erm(41) 23S rRNA 
2058 
residue
Prior chronic 
aminoglycoside exposure
Amikacin 
sensitivity
Minimum inhibitory 
concentration (μg/mL)
16S rRNA  
residue 
1408/1409
M abscessus subsp abscessus cluster
4 No Inducible 2/>16 T28 A No Sensitive 16 A/C
5 Azithromycin Inducible 8/>16 T28 A Nebulised tobramycin Resistant >64 G/C
11 No Inducible 0·06/>16 T28 A No Sensitive 4 A/C
15 No data Inducible 0·5/>16 T28 A No data Resistant >64 A/T
21 No data Inducible 0·5/>16 T28 A No data Sensitive 8 A/C
23 No data Inducible 0·5/>16 T28 A No data Sensitive 8 A/C
M abscessus subsp abscessus non-clustered
13 No Sensitive 0·06/0·06 Deletion A Nebulised tobramycin Sensitive 2 A/C
18 No Sensitive 0·06/0·06 Deletion A No Sensitive 2 A/C
25 No data Sensitive 0·12/0·5 Deletion A No data Sensitive 8 A/C
27 No data Sensitive 0·25/0·5 Deletion A No data Sensitive 16 A/C
M abscessus subsp massiliense cluster 1
8 Azithromycin Resistant >16/>16 Deletion C No Resistant* >64 G/C
12 Azithromycin Resistant >16/>16 Deletion C No Resistant* >64 G/C
14 No Resistant* >16/>16 Deletion C Nebulised tobramycin Resistant >64 G/C
17 Azithromycin Resistant >16/>16 Deletion C No Resistant* >64 G/C
19 No Resistant* >16/>16 Deletion C No Resistant* >64 G/C
20 Azithromycin Resistant >16/>16 Deletion C Nebulised tobramycin Resistant >64 G/C
22 Azithromycin Resistant >16/>16 Deletion C Nebulised tobramycin Resistant >64 G/C
29 Azithromycin Resistant >16/>16 Deletion C Nebulised amikacin Resistant >64 G/C
30 No Resistant* >16/>16 Deletion C No Resistant* >64 G/C
M abscessus subsp massiliense cluster 2
2 No data Resistant >16/>16 Deletion G No data Sensitive 16 A/C
28 Azithromycin Resistant >16/>16 Deletion G No data Sensitive 16 A/C
Antibiotic resistance determined by broth microdilution was compared with molecular analysis of the ribosomal methyltransferase erm(41), and 23S and 16S ribosomal RNA sequences. Isolates from patient 8 
became resistant to aminoglycosides during NTM treatment with an amikacin-based regimen. Resistance deﬁ ned as minimum inhibitory concentration >16 μg/mL for clarithromycin and >64 μg/mL for 
amikacin. *Patients with isolates resistant to clarithromycin or amikacin through ribosomal mutations but with no prior chronic exposure to macrolides or aminoglycosides. 
Table: Antibiotic resistance patterns for M abscessus isolates; by patient number
Articles
1556 www.thelancet.com   Vol 381   May 4, 2013
supply, which is chlorinated on site, was extensively 
sampled and repeatedly found to be culture-negative and 
PCR-negative for mycobacteria. Showerheads, dish-
washers, and bronchosocopes (to which only four of the 
patients within cluster 1 and 2 were exposed before their 
ﬁ rst positive sample) were also shown to be free from 
NTM. Furthermore, samples from the River Cam and 
the Papworth Hospital pond were also negative for 
M abscessus. These ﬁ ndings, together with our genetic 
data, indicate that independent environmental acqui-
sition of M abscessus subsp massiliense from the same 
point source is unlikely. 
We next investigated whether there were opportunities 
for transmission of M abscessus subsp massiliense between 
patients with cystic ﬁ brosis. Although we could not ﬁ nd 
occasions outside the hospital where direct patient-to-
patient transmission might have occurred, we did 
identify clear opportunities for cross-infection within the 
cystic ﬁ brosis centre for all patients from the two 
M abscessus subsp massiliense clusters (ﬁ gure 3). Except 
for the presumed index cases (patient 8 in cluster 1 and 
patient 2 in cluster 2), all previously uninfected patients 
were present at the centre at the same time as an infected 
individual on multiple occasions. 
By contrast, patients infected with the grouped 
M abscessus subsp abscessus isolates had no clear 
opportunities for cross-infection within or outside the 
cystic ﬁ brosis centre (ﬁ gure 3), further supporting our 
view that these isolates represent a dominant circulating 
clone rather than recent transmission within the hospital 
environment.
The possibility of within-hospital transmission of NTM 
was further supported by more detailed epidemiological 
analysis. Individuals within M abscessus subsp massiliense 
Figure 3: Opportunities for patient-to-patient transmission within hospital 
The timelines of individual patients within the M abscessus subsp massiliense clusters 1 and 2 (A) and M abscessus subsp abscessus cluster (B) are shown. Short vertical 
lines denote hospital visits or admissions to Papworth Hospital, and circles denote sputum samples (culture negative [white]; smear negative culture positive 
[half-red]; smear positive [red]). Timelines become red after a positive sputum sample. Potential opportunities for transmission between patients (by virtue of being 
in hospital at the same time as a positive patient) are highlighted by grey vertical bars. All patients within the M abscessus subsp massiliense clusters had opportunities 
for transmission, whereas only two patients within the  M abscessus subsp abscessus cluster had any opportunity for cross-infection.
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cluster 1 (clustered cases; n=9) were compared with 
patients with unclustered M abscessus isolates (reference 
cases; n=15). We assumed that patients might acquire 
infection any time during a 12-month period before their 
ﬁ rst positive sample (period of potential acquisition) and 
might transmit infection at any time from this point 
onwards. For every 100 days during periods of potential 
acquisition, clustered cases were signiﬁ cantly more 
exposed to hospital than reference cases (mean 10·8 days 
vs 4·1 days; p=0·0126), had greater exposure to the cystic 
ﬁ brosis inpatient ward (mean 5·7 days vs 1·5 days; 
p=0·0133) and the cystic ﬁ brosis outpatient department 
(mean 3·9 days vs 2.3 days; p=0·0235), and were more 
likely to be in hospital at the same time as potentially 
infected individuals (4·18 days vs 0·63 days; p=0·0053).
Network analysis (ﬁ gure 4) conﬁ rmed that clustered 
cases were more tightly interconnected than reference 
cases (with connection densities of 0·47 and 0·18, 
respectively) and were all exposed during periods of 
possible acquisition to individuals who had the potential 
to transmit infection, both in the outpatient department 
and inpatient ward. Genetic conﬁ rmation of the detailed 
chain of transmission events between clustered cases 
suggested by the network analysis was not possible 
because of the small number of SNP diﬀ erences between 
patient isolates. We did, however, notice a loose 
correlation between the duration of overlap within 
hospital for pairs of patients and the genomic relatedness 
of their isolates, further supporting inpatient trans-
mission (appendix). No such relation was seen for the 
reference cases.
We next assessed whether the timing of potential trans-
mission events was compatible with the degree of genetic 
divergence seen in isolates from diﬀ erent individuals 
within the M abscessus subsp massiliense clusters (ﬁ gure 1). 
Bayesian analysis was used to estimate a mean mutation 
rate (SNPs per genome per year) of 1·8 (95% CI 0·3–3·3) 
for M abscessus subsp abscessus and 0·47 (0·2–0·8) for 
M abscessus subsp massiliense. This technique also allowed 
us to estimate when the most recent common ancestor 
existed for the various groups of isolates (ﬁ gure 5). In the 
case of both M abscessus subsp massiliense clusters, the 
interpatient most recent common ancestor could be 
dated to the period when opportunities existed for 
hospital-associated transmission, whereas for the grouped 
M abscessus subsp abscessus, it was dated to several decades 
before. Our mutation analysis thus further supports the 
likelihood of transmission of M abscessus subsp massiliense 
between patients with cystic ﬁ brosis. 
Discussion
Whole genome sequencing has provided the ﬁ rst con-
vincing evidence for transmission of M abscessus (panel). 
Although limited to analysis of one centre, our 
study indicates that acquisition of M abscessus subsp 
massiliense by cystic ﬁ brosis patients is frequently 
through cross-infection.
Our analysis revealed three distinct modes of acqui-
sition of M abscessus by patients with cystic ﬁ brosis. We 
recorded numerous examples of independent acqui sition 
of genetically diverse strains of all three subspecies, most 
likely representing independent acquisition from the 
environment. We also found clusters of patients with 
genetically related clones of M abscessus subsp abscessus, 
which although identical by hsp65 PCR techniques, have 
roughly 50–200 base pair diﬀ erences from each other 
and are estimated to have diverged from a common 
ancestor decades ago. These loose clusters are likely to 
represent independent acquisition of a dominant clone 
circulating in the wider community; a pattern frequently 
seen with Pseudomonas aeruginosa.33 Additionally, we 
identiﬁ ed multiple examples of genetically identical or 
Figure 4: Network analysis of patients with clustered and non-clustered M abscessus
Social network analysis of individuals within M abscessus subsp massiliense cluster 1 (clustered cases; n=9) were 
compared with patients with unclustered M abscessus isolates (reference cases; n=15). We assumed that patients 
might acquire infection any time during a 12 month period before their ﬁ rst positive sample and might transmit 
infection at any time from this point onwards. Arrow thickness denotes duration of overlap within diﬀ erent areas 
of the hospital for individuals during periods of potential acquisition of infection with potentially infected 
patients. Arrow direction indicates potential route of transmission. The position of the circles represents the date 
of the ﬁ rst positive culture for M abscessus. Clustered cases were more tightly interconnected (having higher 
network densities) than references cases, were all exposed to individuals who had the potential to transmit 
infection during periods of potential acquisition, and that potential transmission events between them occurred 
both within the outpatients department and/or cystic ﬁ brosis inpatient ward. 
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near-identical strains of M abscessus subsp massiliense 
found in diﬀ erent individuals, indicating direct or 
indirect person-to-person transmission. Since previous 
studies,19,20 done at a time of low infection rates with 
M abscessus, showed genetically unique isolates from 
individual  patients with cystic ﬁ brosis (on the basis of 
PFGE or hsp65 sequencing), we could speculate that 
transmissible clones have emerged over the past decade 
and spread through this patient group in a similar way to 
epidemic strains of P aeruginosa.
Recent transmission of M abscessus subsp massiliense 
is also supported by several lines of evidence. The 
genetic variation of isolates from particular individuals 
is entirely encompassed by that seen within another 
patient’s samples, indicating direct sequential evolution 
of strains—a pattern incompatible with infection from a 
point source. Diversity analysis shows that the genetic 
variation of isolates seen within one person (repre-
senting de novo accumulation of mutations by an 
infecting clone) is often greater than the genetic 
diversity seen between isolates from diﬀ erent indiv-
iduals, once again indicating transmission events 
between patients. By examining patterns of antibiotic 
resistance, we ﬁ nd that the clustered M abscessus subsp 
massiliense strains have high level, constitutive clari-
thromycin and amikacin resistance, which is usually 
only seen in isolates from patients receiving long-
term macrolide and aminoglycoside therapy. However, 
several individuals infected with these resistant isolates 
had no history of relevant antibiotic exposure, again 
further indicating acquisition of another patient’s 
strain. This genetic evidence of transmission was sup-
ported by the fact that we were clearly able to deﬁ ne 
multiple opportunities for transmission of these speciﬁ c 
clones between patients. Furthermore, Bayesian esti-
mates place the age of the most recent common 
ancestral clone for each of the M abscessus subsp 
massiliense clusters within the periods when these trans-
mission opportunities existed. 
Despite our evidence for transmission of M abscessus 
subsp massiliense between patients, the exact mech-
anism of cross-infection remains to be established. 
There are several possibilities. We believe that direct 
person-to-person spread is unlikely. The Cystic Fibrosis 
Centre at Papworth Hospital adopted strict infection 
control policies in 2004 enforcing individual patient 
segregation in accordance with UK Cystic Fibrosis 
Trust guidelines.34 Thus, patients are advised not to 
meet socially and are cared for in individual rooms 
while receiving inpatient treatment and during 
outpatient clinic review. We therefore assume that 
transmission probably occurs indirectly. The ability of 
M abscessus to withstand desiccation and other physical 
stresses and its resistance to many disinfectants35 might 
promote transmission via fomite contamination. Alter-
natively, aerosol generation during physiotherapy and 
lung function testing could lead to cross-infection 
Figure 5: Date of the most recent common ancestors of putatively 
transmitted  M abscessus subsp massiliense strains and opportunities for 
patient-to-patient transmission
Estimates, predicted by Bayesian inference using BEAST,24 of when the most 
recent common ancestor existed for isolates from diﬀ erent patients within 
M abscessus subsp massiliense clusters 1 and 2 and from the two patients 
within the M abscessus subsp abscessus cluster who had transmission 
opportunities. In the case of both M abscessus subsp massiliense clusters, the 
interpatient most recent common ancestor could be dated to the period when 
opportunities existed for hospital-associated transmission (red circles), 
whereas for the grouped M abscessus subsp abscessus, it was dated to several 
decades before.
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Systematic review
Increasing numbers of individuals with cystic ﬁ brosis are becoming infected with the 
multidrug-resistant non-tuberculous mycobacterium (NTM) Mycobacterium abscessus.11–13 
How this organism is acquired is not currently known but there is growing concern that 
person-to-person transmission might occur. We searched Medline and Pubmed for articles 
published in any language before January, 2013, with the keywords “nontuberculous” or 
“Mycobacterium abscessus” for evidence of studies addressing the mechanism of acquisition 
of M abscessus. Several studies have identiﬁ ed shared genotypes between patients with 
cystic ﬁ brosis attending the same clinic, indicating possible transmission,21–23 whereas others 
observed unique strains suggesting no such relationship.19,20 However, all of these studies 
were limited both by the number of patients and the resolution of typing techniques used. 
Our study describes the ﬁ rst use of whole genome sequencing to analyse the mechanisms of 
acquisition of NTM. 
Interpretation
The combination of whole genome sequencing and detailed epidemiological analysis has 
provided the ﬁ rst convincing evidence for transmission of M abscessus. Although limited 
to analysis of one centre, our study indicates that acquisition of this NTM by cystic ﬁ brosis 
patients is frequently through cross-infection and occurs despite conventional infection 
control measures. As such these ﬁ ndings will have profound implications for how patients 
with cystic ﬁ brosis are cared for in hospital. They also raise the possibility for 
cross-infection in other patient groups and with other NTM species.
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through inhalation of airborne water droplets, from 
which NTM have been cultured in the environment.36 
We have also shown that transmission can occur from 
patients with persistently smear-negative, culture-
positive sputum, suggesting that the inoculum needed 
for successful infection could be low. 
Although we cannot exclude the possibility that 
M abscessus subsp abscessus and M abscessus subsp 
bolletii could also be transmissible, our data only 
identiﬁ ed cross-infection events for M abscessus subsp 
massiliense clones, raising the possibility that this 
subspecies might be more infectious. The extent of 
M abscessus cross-infection between individuals in other 
cystic ﬁ brosis centres or indeed among patients without 
cystic ﬁ brosis is unclear, although the sequence of a 
patient isolate from Birmingham is closely related to 
the two M abscessus subsp massiliense clusters we have 
identiﬁ ed, suggesting that this clade is not unique to 
Papworth and could be particularly adapted to cystic 
ﬁ brosis infection. We are currently sequencing isolates 
from across the UK to deﬁ ne the genetic population 
structure and determine the frequency of transmission 
events in other cystic ﬁ brosis centres. In response to 
our ﬁ ndings we have implemented new infection 
control measures including: continuous sputum 
screen ing for NTM of our whole patient cohort; 
outpatient segregation of infected patients within a 
dedicated outpatient clinic with single-use rooms, and 
use of negative pressure rooms for inpatient care. 
However, we cannot yet say whether we have prevented 
further transmission of M abscessus subsp massiliense in 
our patient cohort.
The ﬁ nding of frequent M abscessus subsp massiliense 
transmission in patients with cystic ﬁ brosis raises several 
important questions about current infection control 
measures used in treatment centres, the potential for 
cross-infection in other patient groups and with other 
NTM species, and whether mandatory notiﬁ cation of 
infections with M abscessus complex and routine whole 
genome sequencing might be required to identify and 
control the spread of these organisms. 
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